Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 170 patients (estimated)
- Sponsors
- Chordia Therapeutics, Inc.
- Collaborators
- Theradex
- Tags
- CLK Inhibitor
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1501
- NCT Identifier
- NCT05732103
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.